مجله آنستزیولوژی و مراقبتهای ویژه ایران

Ellis F, Heffron J. Clinical and biochemical aspects of malignant hyperpyrexia. Recent Adv Anaesth Analg. 1985;15:173-207.

Nelson TE. Malignant hyperthermia: a pharmaco-genetic disease of Ca++ regulating proteins. Current mol Med. 2002;2(4):347-69.

Nelson T. Skeletal muscle sarcoplasmic reticulum in the malignant hyperthermia syndrome. Malignant Hyperthermia: Springer; 1987. p. 43-78.

Nelson T, Flewellen E. Current concepts. The malignant hyperthermia syndrome. The N E J Med. 1983; 309(7):416-8.

Hines RL, Marschall K. Stoelting's anesthesia and co-existing disease: Elsevier Health Sciences; 2012.

Fill M, Coronado R, Mickelson JR, Vilven J, Ma J, Jacobson B, et al. Abnormal ryanodine receptor channels in malignant hyperthermia. Biophysical Journal. 1990; 57(3):471-

Kudoh A, Kikuchi A, Wakayama S, Ishihara H, Matsuki A. Malignant hyperthermia triggered by isoflurane and suxamethonium in a patient who underwent apparently uneventful halothane anesthesia previously: a case report. J Anesthesia. 1999; 13(3): 181-4.

Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth. Analg. 2010; 110 (2): 498-507.

Murao K, Umegaki T, Masuzawa M, Inoue S, Nakao S, Shingu K. [Propofol triggers a marked body temperature increase in a patient with fulminant malignant hyperthermia (MH) without inducing other symptoms of MH]. Masui The Japanese J Anesthesiology. 2010; 59(1):92-6.

Fruen BR, Mickelson JR, Roghair TJ, Litterer LA, Louis CF. Effects of propofol on calcium sup 2+ regulation by malignant hyperthermia‐ susceptible muscle membranes. Anesthesiology. 1995; 82 (5): 1274-82.